Stanford to limit drug maker financing
Stanford University is expected to announce that it will severely restrict industry financing of doctors' continuing education at its medical school. The move is due to concern about the influence drug companies may have on medical education. Nearly all doctors in the country must take annual refresher courses that drug makers have long paid for, but Stanford will no longer let drug and device companies specify which courses they wish to finance. Instead, companies will be asked to contribute only to a schoolwide pool of money that can be used for any class, even ones that never mention a company's products.
- Sharp HealthCare Leaves Pioneer ACO Program
- Acute Kidney Injury Gets New Focus
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Interventional Radiology No Longer a Sub-Specialty
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- PCI: Concerns Mount About Appropriateness
- MA an Insurance Proving Ground for Providers
- Transforming Cancer Care
- Targeting Self-Insured Populations